US-guided percutaneous microwave ablation for benign thyroid nodules: a prospective multicenter study

e17593 Background: To evaluate the clinical outcomes between radiofrequency ablation (RFA) and microwave ablation (MWA) in treating benign thyroid nodules (BTNs) with a prospective multicenter study. Methods: The prospective multicenter study achieved the registration of Chinese Clinical Trial Registry (Number: ChiCTR-ONRC-13003087). From January of 2013 to December of 2015, the total number of 1,252 patients with 1351 benign thyroid nodules (BTNs) at eight participating institutions was enrolled in the multicenter study. The ablation devices were applied in the study including RFA system of VIVA RF generator (VIVA RF generator, STARmed, Goyang, Korea) and MWA system of KY-2000 2450MHz microwave system (KY-2000, Kangyou Medical, Nanjing, China). All the procedures of RFA or MWA were performed under ultrasound (US) guidance in each center. Results: The number of target nodules treated by RFA and MWA were 687 in 649 cases and 664 in 603 cases, respectively. For the estimation of efficacy, the mean maximal diameter reduction ratios (MDRRs) of RFA vs. MWA groups at the 3rd, 6th, 12th month and last follow-up were 36.4±17.3% vs. 36.0±23.0% (p = 0.765), 54.1±22.7% vs. 49.3±28.0% (p = 0.005), 64.5±22.1% vs. 57.9±40.1% (p = 0.008) and 65.5±26.0% vs. 58.2±33.5% (p = 0.028), respectively. The mean volume reduction ratios (VRRs) of RFA vs. MWA groups at the 3rd, 6th, 12th month and last follow-up were 67.6±20.3% vs. 64.4±43.5% (p = 0.143), 84.1±13.5% vs. 78.4±48.2% (p = 0.016), 89.6±20.0% vs. 82.5±49.7% (p = 0.035) and 91.3±12.6% vs. 81.1±70.4% (p = 0.045), respectively. For the estimation of safety, for all the complications and side effects encountered at the peri-ablation and follow-up period in two groups, the major, minor complication and side effect rates of RFA vs. MWA group were all no statistical significances with 4.78% vs. 6.63% (p = 0.156), 2.00% vs. 2.49% (p = 0.562) and 4.93% and 4.64% (p = 0.812), respectively. Conclusions: As a conclusion of the prospective multicenter study, both RFA and MWA under US guidance percutaneously are safe and effective techniques for selected patients with BTNs. Larger MDRR and VRR can be achieved in RFA group than the ones in MWA group at 6-month and later follow-up. Clinical trial information: ChiCTR-ONRC-13003087.

Download Full-text

RE: Efficacy and Safety of Radiofrequency Ablation for Benign Thyroid Nodules: A Prospective Multicenter Study

Korean Journal of Radiology ◽

10.3348/kjr.2018.19.3.542 ◽

2018 ◽

Vol 19 (3) ◽

pp. 542 ◽

Cited By ~ 1

Author(s):

Qi Di

Keyword(s):

Radiofrequency Ablation ◽

Multicenter Study ◽

Thyroid Nodules ◽

Efficacy And Safety ◽

Prospective Multicenter Study ◽

Benign Thyroid Nodules ◽

Benign Thyroid

Download Full-text

Ultrasound-guided percutaneous microwave ablation of benign thyroid nodules: experimental and clinical studies

Acta Endocrinologica ◽

10.1530/eje-11-0966 ◽

2012 ◽

Vol 166 (6) ◽

pp. 1031-1037 ◽

Cited By ~ 69

Author(s):

Bing Feng ◽

Ping Liang ◽

Zhigang Cheng ◽

Xiaoling Yu ◽

Jie Yu ◽

...

Keyword(s):

Microwave Ablation ◽

Thyroid Nodules ◽

Ex Vivo ◽

Microwave Antenna ◽

Ultrasound Guided ◽

Internally Cooled ◽

Percutaneous Microwave Ablation ◽

Benign Thyroid Nodules ◽

Benign Thyroid

PurposeTo obtain the treatment parameters of internally cooled microwave antenna and to evaluate the feasibility of ultrasound-guided percutaneous microwave ablation (MWA) for benign thyroid nodules.Materials and methodsMWAs were performed by microwave antenna (16G) in ex vivo porcine liver. The lesion diameters achieved in different groups (20, 25, and 30 W for 3, 5, 7, 10, and 12 min) were compared. The clinical study was approved by the ethics committee. Written informed consent was obtained from all patients. MWA was performed in 11 patients (male to female ratio=1:10; mean age, 50±7 years) with 11 benign thyroid nodules. Ultrasound scan, laboratory data, and clinical symptoms were evaluated before and 1 day and 1, 3, 6, 9, and 12 months after the procedure.ResultsIn ex vivo study, the ablation lesion at 30 W 12 min tended to have appropriate scope and spherical shape. In clinical study, the follow-up periods ranged from 1 to 9 months. At the last follow-up, the largest diameter decreased from 2.9±1.0 (range, 1.6–4.1) to 1.9±0.7 (range, 0.4–3.0) cm (P<0.01), and the volume decreased from 5.30±4.88 (range, 0.89–14.81) to 2.40±2.06 (range, 0.02–6.35) ml (P<0.01). The volume reduction ratio was 45.99±29.90 (range, 10.56–98.15) %. The cosmetic grading score was reduced from 3.20±0.79 to 2.30±0.95 (P<0.05). One patient experienced temporary nerve palsy and was recovered within 2 months after treatment.ConclusionThe internally cooled microwave antenna can yield ideal ablation lesions, and ultrasound-guided percutaneous MWA is a feasible technique for benign thyroid nodules.

Download Full-text

Percutaneous microwave ablation of benign thyroid nodules

Nuklearmedizin ◽

10.3413/nukmed-0678-14-06 ◽

2015 ◽

Vol 54 (01) ◽

pp. 13-19 ◽

Cited By ~ 8

Author(s):

F. Nimsdorf ◽

C. Happel ◽

H. Ackermann ◽

F. Grünwald ◽

H. Korkusuz

Keyword(s):

Microwave Ablation ◽

Thyroid Nodules ◽

Volume Reduction ◽

Clinical Issue ◽

New Approach ◽

99Mtc Mibi ◽

The Impact ◽

Percutaneous Microwave Ablation ◽

Benign Thyroid Nodules ◽

Benign Thyroid

SummaryAim: Thyroid nodules represent a common clinical issue. Amongst other minimally invasive procedures, percutaneous microwave ablation (MWA) poses a promising new approach. The goal of this retrospective study is to find out if there is a correlation between volume reduction after 3 months and 99mTcuptake reduction of treated thyroid nodules. Patients, methods: 14 patients with 18 nodules were treated with MWA. Pre-ablative assessment included sonographical and functional imaging of the thyroid with 99mTcpertechnetate and 99mTc-MIBI. Additionally, patients underwent thyroid scintigraphy 24 hours after ablation in order to evaluate the impact of the treatment on a functional level and to ensure sufficient ablation of the targeted area. At a 3-month follow-up, ultrasound examination was performed to assess nodular volume reduction. Results: Mean relative nodular volume reduction after three months was 55.4 ± 17.9% (p < 0.05). 99mTcuptake 24 hours after treatment was 45.2 ± 31.9% (99mTc-MIBI) and 35.7 ± 20.3% (99mTcpertechnetate) lower than prior to ablation (p < 0.05). Correlating reduction of volume and 99mTc-uptake, Pearson's r was 0.41 (p < 0.05) for nodules imaged with 99mTc-MIBI and –0.98 (p < 0.05) for 99mTc-pertechnetate. According to scintigraphy 99.6 ± 22.6% of the determined target area could be successfully ablated. Conclusions: MWA can be considered as an efficient, low-risk and convenient new approach to the treatment of benign thyroid nodules. Furthermore, scintigraphy seems to serve as a potential prognostic tool for the later morphological outcome, allowing rapid evaluation of the targeted area in post-ablative examination.

Download Full-text